What is Sift Bio?
Sift Bio is at the forefront of developing advanced immunotherapy boosters designed to augment the efficacy of existing cancer therapies. Leveraging cutting-edge artificial intelligence and high-throughput cellular screening methodologies, the company aims to discover and engineer novel candidates that significantly improve immune cell performance. This strategic approach is geared towards achieving better patient outcomes in oncology, positioning Sift Bio as a key innovator in the competitive biotech landscape.
How much funding has Sift Bio raised?
Sift Bio has raised a total of $3.7M across 1 funding round:
Angel/Pre-Seed
$3.7M
Angel/Pre-Seed (2026): $3.7M with participation from Lifespan Vision Ventures, Freeflow Ventures, and Eisai Innovation, Inc.
Key Investors in Sift Bio
Lifespan Vision Ventures
Lifespan Vision Ventures is an investor focused on diagnostics and therapeutics for longevity and aging reversal, aiming to extend healthy human lifespans. They concentrate on advancements in joints, heart, skin, and muscles, financing game-changing technologies in the longevity field.
Freeflow Ventures
Freeflow Ventures is an early-stage venture firm investing in deep tech solutions for human and planetary health, established within the Caltech entrepreneurial community. They support science-driven startups with proprietary IP, AI, and machine learning, assisting with fundraising, marketing, and strategy.
Eisai Innovation, Inc.
Eisai Innovation, Inc. is part of Eisai, a global pharmaceutical company focused on oncology and neurology. They are dedicated to realizing their human health care (hhc) philosophy by delivering innovative products and solutions to address unmet medical needs, including neglected tropical diseases.
What's next for Sift Bio?
The substantial enterprise-level financing indicates Sift Bio is poised for significant scaling and market expansion. This strategic investment will likely fuel further research and development, accelerate clinical trials, and bolster commercialization efforts. The company's focus on AI-driven discovery in immunotherapy suggests a trajectory towards becoming a leader in precision oncology, with potential for future strategic partnerships or acquisitions within the pharmaceutical sector.
See full Sift Bio company page
